Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-07 Dornase alfa
| Dornase Alfa |
|
Formulary
|
Pulmozyme® 2500 U/ 2.5ml, nebuliser solution |
 NHS England Clinical Commissioning Policy:Inhaled Therapy for Adults and Children with Cystic Fibrosis |
|
Links
NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma- Asthma action plan child: Asthma UK
- Asthma management plan: Asthma UK
- Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (G551D gene)
- LSCMMG: Asthma Treatment Guideline for Adults (aged 12 and over)
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: COPD Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing
- MHRA: Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing
- MHRA: Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing
- MHRA: Kaftrio▼ (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effects
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NHS England Clinical Commissioning Policy:Inhaled Therapy for Adults and Children with Cystic Fibrosis
- NHSE: Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
- NHSE: NHS England commissioning statement: Arrangements for access to cystic fibrosis transmembrane conductance regulator (CFTR) modulators for licensed and off-label use in patients with cystic fibrosis
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
- NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
- NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
- NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
- NICE: Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]